NIAID-Led Study of mRNA Vaccine Supports Advance to Phase 3 Human Trials
Two doses of an experimental vaccine to prevent coronavirus disease 2019 (COVID-19) induced robust immune responses and rapidly controlled the coronavirus in the upper and lower airways of rhesus macaques exposed to SARS-CoV-2, report scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. SARS-CoV-2 is the virus that causes COVID-19.
The candidate vaccine, mRNA-1273, was co-developed by scientists at the NIAID Vaccine Research Center and at Moderna, Inc., Cambridge, Massachusetts. The animal study results published online today in the New England Journal of Medicine complement recently reported interim results from an NIAID-sponsored Phase 1 clinical trial of mRNA-1273. The candidate mRNA-1273 vaccine is manufactured by Moderna.
In this study, three groups of eight rhesus macaques received two injections of 10 or 100 micrograms (µg) of mRNA-1273 or a placebo. Injections were spaced 28 days apart. Vaccinated macaques produced high levels of neutralizing antibodies directed at the surface spike protein used by SARS-CoV-2 to attach to and enter cells. Notably, say the investigators, animals receiving the 10-µg or 100-µg dose vaccine candidate produced neutralizing antibodies in the blood at levels well above those found in people who recovered from COVID-19.
The experimental vaccine also induced Th1 T-cell responses but not Th2 responses. Induction of Th2 responses has been associated with a phenomenon called vaccine-associated enhancement of respiratory disease (VAERD). Vaccine-induced Th1 responses have not been associated with VAERD for other respiratory diseases. In addition, the experimental vaccine induced T follicular helper T-cell responses that may have contributed to the robust antibody response.
Four weeks after the second injection, all the macaques were exposed to SARS-CoV-2 via both the nose and the lungs. Remarkably, after two days, no replicating virus was detectable in the lungs of seven out of eight of the macaques in both vaccinated groups, while all eight placebo-injected animals continued to have replicating virus in the lung. Moreover, none of the eight macaques vaccinated with 100 µg of mRNA-1273 had detectable virus in their noses two days after virus exposure. This is the first time an experimental COVID-19 vaccine tested in nonhuman primates has been shown to produce such rapid viral control in the upper airway, the investigators note. A COVID-19 vaccine that reduces viral replication in the lungs would limit disease in the individual, while reducing shedding in the upper airway would potentially lessen transmission of SARS-CoV-2 and consequently reduce the spread of disease, they add.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- ‘My arm went blue’: Chinese execs tested Covid-19 vaccine to lead by exampleon October 6, 2020 at 8:37 pm
A senior figure at a Chinese pharmaceutical company that tested Covid-19 vaccines on its own executives before human trials took place has defended the decision, saying they were "leading by example".
- Expect Pfizer/BioNTech and Moderna Coronavirus Vaccine Data Readouts in November-December, U.S. Vaccine Program Head Sayson October 6, 2020 at 8:21 pm
The head of the U.S. government's Operation Warp Speed COVID-19 vaccine program, Moncef Slaoui, said he expects phase 3 clinical trial data for multiple coronavirus vaccines in the ...
- U.S. vaccine program head Slaoui expects Pfizer, Moderna vaccine data readouts in Nov-Decon October 6, 2020 at 5:23 pm
The chief adviser for the U.S. government's Operation Warp Speed COVID-19 vaccine program, Moncef Slaoui, on Tuesday said efficacy data readouts are expected from Pfizer Inc and Moderna Inc between ...
- Is the FDA Too Cautious in Its Approach for Approving COVID-19 Vaccines?on October 6, 2020 at 4:05 pm
The same day the White House reportedly first blocked and then scrambled to approve under pressure the Food and Drug Administration's (FDA) proposed guideline that COVID-19 clinical trial vaccine ...
- White House reportedly blocked FDA’s new coronavirus vaccine guidelineson October 6, 2020 at 3:52 pm
Reports say the White House disagrees with new coronavirus vaccine approval guidelines from the FDA which would make it impossible for a vaccine candidate to seek emergency use authorization ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- How Moderna's Slowing COVID-19 Vaccine Enrollment Could Delay Interim Readouton October 5, 2020 at 2:20 pm
Moderna Inc (NASDAQ: MRNA)'s CEO said last week that it will not seek emergency use authorization for its coronavirus vaccine candidate mRNA-1273 before the ...
- The Zacks Analyst Blog Highlights: MRNA, AZN, PFE and BNTXon October 5, 2020 at 12:47 pm
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks ...
- 2 Fast-Growing Stocks Under $100on October 4, 2020 at 4:38 am
The company's vaccine candidate, mRNA-1273, is one of a small group currently being evaluated in late-stage clinical trials. Other companies with coronavirus vaccine candidates enrolled in phase 3 ...
- Moderna Coronavirus Vaccine May Not Be Ready Before US Electionson October 2, 2020 at 8:50 am
MRNA is unlikely to file a regulatory application seeking emergency use authorization (“EUA”) for its coronavirus vaccine candidate, mRNA-1273, before the U.S. presidential election scheduled on Nov 3 ...
- Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adultson October 1, 2020 at 3:15 am
We conducted a phase 1, dose-escalation, open-label trial of a messenger RNA vaccine, mRNA-1273, which encodes the stabilized prefusion SARS-CoV-2 spike protein (S-2P) in healthy adults.